Format

Send to

Choose Destination
Vaccine. 2011 Sep 23;29(42):7267-75. doi: 10.1016/j.vaccine.2011.07.021. Epub 2011 Jul 21.

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.

Author information

1
Merck and Co., 770 Sumneytown Pike, West Point, PA 19486, United States. beth-ann.coller@merck.com

Abstract

Challenges associated with the interference observed between the dengue virus components within early tetravalent live-attenuated vaccines led many groups to explore the development of recombinant subunit based vaccines. Initial efforts in the field were hampered by low yields and/or improper folding, but the use of the Drosophila S2 cell expression system provided a mechanism to overcome these limitations. The truncated dengue envelope proteins (DEN-80E) for all four dengue virus types are expressed in the S2 system at high levels and have been shown to maintain native-like conformation. The DEN-80E proteins are potent immunogens when formulated with a variety of adjuvants, inducing high titer virus neutralizing antibody responses and demonstrating protection in both mouse and non-human primate models. Tetravalent vaccine formulations have shown no evidence of immune interference between the four DEN-80E antigens in preclinical models. Based on the promising preclinical data, the recombinant DEN-80E proteins have now advanced into clinical studies. An overview of the relevant preclinical data for these recombinant proteins is presented in this review.

PMID:
21777637
PMCID:
PMC3179979
DOI:
10.1016/j.vaccine.2011.07.021
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center